Thrombocytopenia risks in ARDS COVID-19 patients treated with high-dose linezolid during vvECMO therapy: an observational study
Само за регистроване кориснике
Аутори
Kovačević, PeđaMilaković, Dragana
Kovačević, Tijana
Barišić, Vedrana
Dragić, Saša
Zlojutro, Biljana
Miljković, Branislava
Vučićević, Katarina
Rizwan, Zeeshan
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
Patients treated with ECMO are at great risk of nosocomial infections, and around 10% of isolates are gram-positive pathogens. Linezolid (LZD) is effective in the treatment of these infections but appropriate dosing is challenging. The aim was to evaluate the occurrence of thrombocytopenia during ECMO when treated with LZD. An LZD trough concentration of 8 mg/L was set as the cutoff value for thrombocytopenia occurrence among critically ill patients who received parenteral LZD therapy at a dose of 600 mg every 8 h during ECMO. Eleven patients were included in this prospective observational study. Median LZD trough concentrations were 7.85 (interquartile range (IQR), 1.95-11) mg/L. Thrombocytopenia was found in 81.8% of patients. Based on the median LZD trough concentrations cutoff value, patients were divided into two groups, 1.95 (IQR, 0.91–3.6) and 10.3 (IQR, 9.7–11.7) mg/L, respectively. Median platelet values differed significantly between groups on admission, ECMO day 0, ECMO day ...1, and LZD sampling day [194 and 152.5, (p < 0.05)], [113 and 214, (p < 0.05)], [76 and 147.5, (p < 0.01)], and [26 and 96.5, (p < 0.01)], respectively. Duration of LZD therapy was similar between the groups. Significant platelet reduction was observed in both groups, emphasizing the need for closer monitoring to prevent LZD-associated thrombocytopenia.
Кључне речи:
ECMO / ARDS / Dosing regime / Linezolid / Safety / ThrombocytopeniaИзвор:
Naunyn-Schmiedeberg's Archives of PharmacologyИздавач:
- Springer Science and Business Media Deutschland GmbH
Финансирање / пројекти:
- Министарство науке, технолошког развоја и иновација Републике Србије, институционално финансирање - 200161 (Универзитет у Београду, Фармацеутски факултет) (RS-MESTD-inst-2020-200161)
- In 2022, a research grant support was approved for this study by the Zoll Foundation.
DOI: 10.1007/s00210-024-03136-1
ISSN: 0028-1298
PubMed: 38713258
Scopus: 2-s2.0-85192266888
Институција/група
PharmacyTY - JOUR AU - Kovačević, Peđa AU - Milaković, Dragana AU - Kovačević, Tijana AU - Barišić, Vedrana AU - Dragić, Saša AU - Zlojutro, Biljana AU - Miljković, Branislava AU - Vučićević, Katarina AU - Rizwan, Zeeshan UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5631 AB - Patients treated with ECMO are at great risk of nosocomial infections, and around 10% of isolates are gram-positive pathogens. Linezolid (LZD) is effective in the treatment of these infections but appropriate dosing is challenging. The aim was to evaluate the occurrence of thrombocytopenia during ECMO when treated with LZD. An LZD trough concentration of 8 mg/L was set as the cutoff value for thrombocytopenia occurrence among critically ill patients who received parenteral LZD therapy at a dose of 600 mg every 8 h during ECMO. Eleven patients were included in this prospective observational study. Median LZD trough concentrations were 7.85 (interquartile range (IQR), 1.95-11) mg/L. Thrombocytopenia was found in 81.8% of patients. Based on the median LZD trough concentrations cutoff value, patients were divided into two groups, 1.95 (IQR, 0.91–3.6) and 10.3 (IQR, 9.7–11.7) mg/L, respectively. Median platelet values differed significantly between groups on admission, ECMO day 0, ECMO day 1, and LZD sampling day [194 and 152.5, (p < 0.05)], [113 and 214, (p < 0.05)], [76 and 147.5, (p < 0.01)], and [26 and 96.5, (p < 0.01)], respectively. Duration of LZD therapy was similar between the groups. Significant platelet reduction was observed in both groups, emphasizing the need for closer monitoring to prevent LZD-associated thrombocytopenia. PB - Springer Science and Business Media Deutschland GmbH T2 - Naunyn-Schmiedeberg's Archives of Pharmacology T1 - Thrombocytopenia risks in ARDS COVID-19 patients treated with high-dose linezolid during vvECMO therapy: an observational study DO - 10.1007/s00210-024-03136-1 ER -
@article{ author = "Kovačević, Peđa and Milaković, Dragana and Kovačević, Tijana and Barišić, Vedrana and Dragić, Saša and Zlojutro, Biljana and Miljković, Branislava and Vučićević, Katarina and Rizwan, Zeeshan", abstract = "Patients treated with ECMO are at great risk of nosocomial infections, and around 10% of isolates are gram-positive pathogens. Linezolid (LZD) is effective in the treatment of these infections but appropriate dosing is challenging. The aim was to evaluate the occurrence of thrombocytopenia during ECMO when treated with LZD. An LZD trough concentration of 8 mg/L was set as the cutoff value for thrombocytopenia occurrence among critically ill patients who received parenteral LZD therapy at a dose of 600 mg every 8 h during ECMO. Eleven patients were included in this prospective observational study. Median LZD trough concentrations were 7.85 (interquartile range (IQR), 1.95-11) mg/L. Thrombocytopenia was found in 81.8% of patients. Based on the median LZD trough concentrations cutoff value, patients were divided into two groups, 1.95 (IQR, 0.91–3.6) and 10.3 (IQR, 9.7–11.7) mg/L, respectively. Median platelet values differed significantly between groups on admission, ECMO day 0, ECMO day 1, and LZD sampling day [194 and 152.5, (p < 0.05)], [113 and 214, (p < 0.05)], [76 and 147.5, (p < 0.01)], and [26 and 96.5, (p < 0.01)], respectively. Duration of LZD therapy was similar between the groups. Significant platelet reduction was observed in both groups, emphasizing the need for closer monitoring to prevent LZD-associated thrombocytopenia.", publisher = "Springer Science and Business Media Deutschland GmbH", journal = "Naunyn-Schmiedeberg's Archives of Pharmacology", title = "Thrombocytopenia risks in ARDS COVID-19 patients treated with high-dose linezolid during vvECMO therapy: an observational study", doi = "10.1007/s00210-024-03136-1" }
Kovačević, P., Milaković, D., Kovačević, T., Barišić, V., Dragić, S., Zlojutro, B., Miljković, B., Vučićević, K.,& Rizwan, Z..Thrombocytopenia risks in ARDS COVID-19 patients treated with high-dose linezolid during vvECMO therapy: an observational study. in Naunyn-Schmiedeberg's Archives of Pharmacology Springer Science and Business Media Deutschland GmbH.. https://doi.org/10.1007/s00210-024-03136-1
Kovačević P, Milaković D, Kovačević T, Barišić V, Dragić S, Zlojutro B, Miljković B, Vučićević K, Rizwan Z. Thrombocytopenia risks in ARDS COVID-19 patients treated with high-dose linezolid during vvECMO therapy: an observational study. in Naunyn-Schmiedeberg's Archives of Pharmacology.. doi:10.1007/s00210-024-03136-1 .
Kovačević, Peđa, Milaković, Dragana, Kovačević, Tijana, Barišić, Vedrana, Dragić, Saša, Zlojutro, Biljana, Miljković, Branislava, Vučićević, Katarina, Rizwan, Zeeshan, "Thrombocytopenia risks in ARDS COVID-19 patients treated with high-dose linezolid during vvECMO therapy: an observational study" in Naunyn-Schmiedeberg's Archives of Pharmacology, https://doi.org/10.1007/s00210-024-03136-1 . .